|
|
Post by jbvegas on Apr 28, 2016 13:34:40 GMT -5
"The trend is your friend until the end." This has been said by many for years. I may regret this, but I sold it all today. Some I bought in the $3's, some in the $4's and some in the low $5's. I even bought more at $0.74. I'm done. I agree with all of the optimism that I've been fed through the FDA approval and the attempts by SNY to market Afrezza and all of the drug reps working hard and the amazing product itself. And on and on ad nauseum. Save your comments I've already been thinking of what to do here for a while. I'm done waiting a while. I'm out. My end is today. Will I get back in when the chart starts moving above $3? Will you? Maybe. I wish you all the best. All of you. Thanks for the memories Al. Read more: mnkd.proboards.com/thread/5496/honest#ixzz4799h1UKW |
|
|
|
Post by trondisc on Apr 28, 2016 16:35:02 GMT -5
The trend is not my friend. MannKind is going to hit 1.30 tomorrow. MNKD probably drifts to 1.30 tomorrow. After hearing past CC days ago I'm scared sh*tless for May "announcements." The reason for my fear...does ANY large cap BIOPHARMA see value in Technosphere?! They say price is truth and once it hits 1.30 you have to ask yourself beyond the short sellers...why has their been no expressed interest by any BP after sandbagger Sanofi?
|
|
|
|
Post by _neil on Apr 28, 2016 18:40:17 GMT -5
Sometimes what's visible is the whole truth. There are no takers for Afrezza because it wasn't a big problem to shoot up insulin with a pen. Hindsight is 20/20 but for the hurdles that patients and prescribers have to go through for Afrezza, the benefits are not worthwhile. Yes, the reduced b1ac is great but we as longs are have to take off the twitter goggles and ask if there's a statistical significance in the reproducibility of results (If you are convinced otherwise, good for you- a big red number in my portfolio tells me I've been duped) . The sharp fall in refill rates tells me that the drug is an overwhelming 'meh'. The non-inferior product will have non-inferior results. MNKD should get real and price it like the non-inferior product that it is.
My prediction is that we will see a PPS of 0.70-0.80 by May 15.
Also, no viable candidate for TS in the decade of MNKD's existence should also be a big red flag. The company can tout having 'several' conversations with partners or several other drug candidates but truth is, they have nothing. And I would do what they are doing too.. show a brave face and live to fight another day. If I am being paid hundreds of thousands to try, why not hang on? After Mann, it's not like any execs are putting their personal wealth into the company.
|
|
|
|
Post by mnholdem on Apr 28, 2016 18:51:59 GMT -5
|
|
|
|
Post by mnkdnewbie on Apr 28, 2016 19:03:28 GMT -5
For second I thought I was reading a frag post on ymb....
|
|
|
|
Post by centralcoastinvestor on Apr 28, 2016 19:26:09 GMT -5
Oh yeah, baby, I luv this part. We've been here before over the years. It's the place that separates the men from the boys, the chaff from the wheat. Like the weeks leading up to ADCOM, the naysaying and pundits reporting that MannKind would soon be bankrupt. It happened again the day the FDA approved Afrezza, with a false report that was published minutes before EOD, dropping the share price nearly $2 in less than ten minutes. The truth came out and MNKD recovered after hours, then rallied nearly 300% in the following weeks. Many capitulated during those low points. Some will this time, too, but not as many. Certainly not enough for shorts to find the number of shares they're going to need to buy before long.     I've owned stock in MannKind since 2007. Didn't sell through Adcom. Didn't sell through FDA approval. For better or worse, I will see this through to the end. I know that good investing says it should never be personal. But for me, to be a part of the ultimate success of Al's vision, I just can't miss that. Even if it means the risk of losing it all. For me, it is personal. |
|
|
|
Post by bioexec25 on Apr 28, 2016 20:05:27 GMT -5
Centralcoast nowhere near as Long for as long but just completely agree with your brief albeit substantive comment. This is indeed personal.
|
|
|
|
Post by sportsrancho on Apr 28, 2016 20:10:35 GMT -5
Tone out the noise! Stop reading what Adam says. This is what they want. To shake you loose! I know many longs who are buying all they can, thanking god for this price. And now the new BS is that's Matts just hanging on for his pay check! That could not be more wrong. People's anger will change from being mad at management to feeling dupped by WS! Afrezza is good as it gets! Here to stay, buying more in May:-). sports
|
|
|
|
Post by papanigon on Apr 28, 2016 20:26:03 GMT -5
"The trend is your friend until the end." This has been said by many for years. I may regret this, but I sold it all today. Some I bought in the $3's, some in the $4's and some in the low $5's. I even bought more at $0.74. I'm done. I agree with all of the optimism that I've been fed through the FDA approval and the attempts by SNY to market Afrezza and all of the drug reps working hard and the amazing product itself. And on and on ad nauseum. Save your comments I've already been thinking of what to do here for a while. I'm done waiting a while. I'm out. My end is today. Will I get back in when the chart starts moving above $3? Will you? Maybe. I wish you all the best. All of you. Thanks for the memories Al. Read more: mnkd.proboards.com/thread/5496/honest#ixzz4799h1UKWFor me, there is still to much upside to consider selling. We have been dragged through the coals and apparently create a cult like atmosphere to some writers. Faith will be my friend to end, the trends can make a person go insane. |
|
|
|
Post by greg on Apr 28, 2016 20:37:50 GMT -5
Sometimes what's visible is the whole truth. There are no takers for Afrezza because it wasn't a big problem to shoot up insulin with a pen. Hindsight is 20/20 but for the hurdles that patients and prescribers have to go through for Afrezza, the benefits are not worthwhile. Yes, the reduced b1ac is great but we as longs are have to take off the twitter goggles and ask if there's a statistical significance in the reproducibility of results (If you are convinced otherwise, good for you- a big red number in my portfolio tells me I've been duped) . The sharp fall in refill rates tells me that the drug is an overwhelming 'meh'. The non-inferior product will have non-inferior results. MNKD should get real and price it like the non-inferior product that it is. My prediction is that we will see a PPS of 0.70-0.80 by May 15. Also, no viable candidate for TS in the decade of MNKD's existence should also be a big red flag. The company can tout having 'several' conversations with partners or several other drug candidates but truth is, they have nothing. And I would do what they are doing too.. show a brave face and live to fight another day. If I am being paid hundreds of thousands to try, why not hang on? After Mann, it's not like any execs are putting their personal wealth into the company. hey __neil, why are you still here?  i just reviewed your posting history and all you do is dump on the company. you claim to have lost a lot of money and are now out, so why don't you just go away? is your life so empty you have to hang around here and spread your misery??? |
|
|
|
Post by _neil on Apr 28, 2016 22:00:53 GMT -5
Just offering my opinions same as everyone else, greg..
I'm grateful I don't need your approval to post. Cheers and good luck!
|
|
|
|
Post by peppy on Apr 29, 2016 7:38:59 GMT -5
Sometimes what's visible is the whole truth. There are no takers for Afrezza because it wasn't a big problem to shoot up insulin with a pen. Hindsight is 20/20 but for the hurdles that patients and prescribers have to go through for Afrezza, the benefits are not worthwhile. Yes, the reduced b1ac is great but we as longs are have to take off the twitter goggles and ask if there's a statistical significance in the reproducibility of results (If you are convinced otherwise, good for you- a big red number in my portfolio tells me I've been duped) . The sharp fall in refill rates tells me that the drug is an overwhelming 'meh'. The non-inferior product will have non-inferior results. MNKD should get real and price it like the non-inferior product that it is. My prediction is that we will see a PPS of 0.70-0.80 by May 15. Also, no viable candidate for TS in the decade of MNKD's existence should also be a big red flag. The company can tout having 'several' conversations with partners or several other drug candidates but truth is, they have nothing. And I would do what they are doing too.. show a brave face and live to fight another day. If I am being paid hundreds of thousands to try, why not hang on? After Mann, it's not like any execs are putting their personal wealth into the company. hey __neil, why are you still here? i just reviewed your posting history and all you do is dump on the company. you claim to have lost a lot of money and are now out, so why don't you just go away? is your life so empty you have to hang around here and spread your misery???That is my story and I am sticking to it. frightening 
|
|
i just reviewed your posting history and all you do is dump on the company. you claim to have lost a lot of money and are now out, so why don't you just go away? is your life so empty you have to hang around here and spread your misery???
